On October 17, 2016, FDA announced “that it has awarded 21 new clinical trial research grants totaling more than $23 million over the next four years to boost the development of products for patients with rare diseases. These new grants were awarded to principal investigators from academia and industry with research spanning domestic and international clinical sites…FDA awards the grants through the Orphan Products Clinical Trials Grants Program to encourage clinical development of drugs, biologics, medical devices, or medical foods for use in rare diseases…A total of 68 grant applications were received for this fiscal year, with a funding rate of 31 percent (21/68).”
Click here for the full story, here to talk to PDG’s grant writer, or here for FDA’s Information on the Orphan Products Clinical Trials Grants Program
